简
/
繁
/
EN
About Us
R&D
Products
News
Careers
Investors
Contact us
Investors
（02186.HK）
HK$
➚
%
Volume(M)
0thousand
Turnover(HK $)
0thousand
Data as of：
Announcement & Circular
Corporate Governance
Financial Results
IR Activities
Contact IR
Year
2022
2023
2024
2025
2026
06
2026-11
VOLUNTARY ANNOUNCEMENT CDE APPROVAL OF IND APPLICATION IN CHINA FOR BA2201, A TL1A/IL-23 BISPECIFIC ANTIBODY FOR THE TREATMENT OF IBD (105KB)
05
2026-11
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2026
30
2026-10
VOLUNTARY ANNOUNCEMENT THE COMPANY ENTERS INTO LICENSING AGREEMENT FOR DENOSUMAB INJECTION 60 MG IN JAPAN
22
2026-10
VOLUNTARY ANNOUNCEMENT FIRST SUBJECT ENROLLED IN PHASE I CLINICAL TRIAL OF BA1203 (A MASKED ANTI-PD-1/IL-2 FUSION PROTEIN) IN CHINA
09
2026-10
CONTINUING CONNECTED TRANSACTIONS PROMOTION COOPERATION AGREEMENT
07
2026-10
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
29
2026-09
INTERIM REPORT 2026
17
2026-09
Next Day Disclosure Return
14
2026-09
VOLUNTARY ANNOUNCEMENT CDE APPROVAL OF IND APPLICATION FOR BA1203 (A MASKED ANTI-PD-1/IL-2 FUSION PROTEIN)
11
2026-09
Next Day Disclosure Return
1
2
3
4
5
Follow me
鲁公网安备37069102000284